» Articles » PMID: 25994018

Intra-tumor Genetic Heterogeneity and Alternative Driver Genetic Alterations in Breast Cancers with Heterogeneous HER2 Gene Amplification

Abstract

Background: HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, heterogeneous distribution of HER2 gene amplification can be found, which creates clinically challenging scenarios. Currently, breast cancers with HER2 amplification/overexpression in just over 10% of cancer cells are considered HER2-positive for clinical purposes; however, it is unclear as to whether the HER2-negative components of such tumors would be driven by distinct genetic alterations. Here we sought to characterize the pathologic and genetic features of the HER2-positive and HER2-negative components of breast cancers with heterogeneous HER2 gene amplification and to define the repertoire of potential driver genetic alterations in the HER2-negative components of these cases.

Results: We separately analyzed the HER2-negative and HER2-positive components of 12 HER2 heterogeneous breast cancers using gene copy number profiling and massively parallel sequencing, and identified potential driver genetic alterations restricted to the HER2-negative cells in each case. In vitro experiments provided functional evidence to suggest that BRF2 and DSN1 overexpression/amplification, and the HER2 I767M mutation may be alterations that compensate for the lack of HER2 amplification in the HER2-negative components of HER2 heterogeneous breast cancers.

Conclusions: Our results indicate that even driver genetic alterations, such as HER2 gene amplification, can be heterogeneously distributed within a cancer, and that the HER2-negative components are likely driven by genetic alterations not present in the HER2-positive components, including BRF2 and DSN1 amplification and HER2 somatic mutations.

Citing Articles

Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer.

Fang K, Ohihoin A, Liu T, Choppavarapu L, Nosirov B, Wang Q Genome Med. 2024; 16(1):134.

PMID: 39558215 PMC: 11572372. DOI: 10.1186/s13073-024-01407-3.


may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.

Jia Y, Liu M, Liu H, Liang W, Zhu Q, Wang C Cancer Biol Ther. 2024; 25(1):2425134.

PMID: 39555702 PMC: 11581156. DOI: 10.1080/15384047.2024.2425134.


NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

Jacobs S, Wang Y, Abraham J, Feng H, Montero A, Lipchik C Breast Cancer Res. 2024; 26(1):69.

PMID: 38650031 PMC: 11036567. DOI: 10.1186/s13058-024-01823-8.


Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth.

Lacy M, Jenner A Bull Math Biol. 2024; 86(4):43.

PMID: 38502371 PMC: 10950993. DOI: 10.1007/s11538-024-01272-6.


In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla.

Guz W, Podgorski R, Bober Z, Aebisher D, Truszkiewicz A, Olek M Int J Mol Sci. 2024; 25(3).

PMID: 38338997 PMC: 10855746. DOI: 10.3390/ijms25031719.


References
1.
Hammond M, Hayes D, Dowsett M, Allred D, Hagerty K, Badve S . American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16):2784-95. PMC: 2881855. DOI: 10.1200/JCO.2009.25.6529. View

2.
Shiu K, Natrajan R, Geyer F, Ashworth A, Reis-Filho J . DNA amplifications in breast cancer: genotypic-phenotypic correlations. Future Oncol. 2010; 6(6):967-84. DOI: 10.2217/fon.10.56. View

3.
Lockwood W, Chari R, Coe B, Thu K, Garnis C, Malloff C . Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med. 2010; 7(7):e1000315. PMC: 2910599. DOI: 10.1371/journal.pmed.1000315. View

4.
Yang Z, Liu G, Bollig-Fischer A, Giroux C, Ethier S . Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 2010; 70(21):8487-97. PMC: 3089754. DOI: 10.1158/0008-5472.CAN-10-1013. View

5.
Hanna W, Ruschoff J, Bilous M, Coudry R, Dowsett M, Osamura R . HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 2013; 27(1):4-18. DOI: 10.1038/modpathol.2013.103. View